An Myocardial Infarction Market, By Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors

Myocardial Infarction Market, By Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics and Thrombolytics), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Myocardial Infarction is also known as heart attack. Heart attack occurs when one of the coronary arteries of the heart becomes suddenly blocked or has extremely slow blood flow.
The formation of a blood clot is the most common cause of a sudden blockage in a coronary artery (thrombus). The blood clot usually forms inside a coronary artery that has already been narrowed by atherosclerosis, a condition in which fatty deposits (plaques) accumulate along the inside wall of the artery.
Chest discomfort, pain, or discomfort in the upper body, shortness of breath, sweating, indigestion, dizziness, or extreme weakness, and anxiety are all symptoms of a heart attack. ECG and blood tests are conducted to diagnose heart attack. Drugs such as vasodilators, aspirin, and beta blockers are used to treat heart attack.

Market Dynamics

Market players and non-profit organizations are focused on initiatives related to heart attack, which is expected to contribute to the growth of the global myocardial infarction market over the forecast period. For instance, on May 17, 2021, the American College of Cardiology (ACC), a non-profit medical association, announce d that its’ Global Heart Attack Treatment Initiative (GHATI) had measurable positive effects on heart attack care delivery in low-and middle-income countries. The initiative was launched in 2019 with the goal of improving heart attack outcomes in low and middle-income countries by encouraging adherence to medical therapy based on guidelines.

Market players are focusing on product launches which is expected to strengthen their position in the global myocardial infarction market. For instance, on June 1, 2021, AstraZeneca plc., a leading international biopharmaceutical company, announced that its' drug Brilinta (ticagrelor) have been approved by the U.S. Food and Drug Administration (FDA), to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.

Market players and government organizations are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, which is expected to drive the growth of the global myocardial infarction market. For instance, on October 4, 2021, Amgen Inc., a multinational biotechnology company, announced a new collaboration with two National Health Service (NHS) organizations in the UK: the North West Coast Innovation Agency and Imperial College Health Partners. This collaboration will aid in the fight against the "silent killer" of high cholesterol along the North West Coast of England, an area plagued by heart attacks, strokes, and premature death by cardiovascular diseases.

Key features of the study:
This report provides an in-depth analysis of global myocardial infarction market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global myocardial infarction market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global myocardial infarction market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global myocardial infarction market.

Detailed Segmentation:
Global Myocardial Infarction Market, By Drug Class:
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Antithrombotic Agents
Beta-adrenergic Blockers
Vasodilators
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin-receptor Blockers
Analgesics
Thrombolytics
Global Myocardial Infarction Market, By Route of Administration:
Oral
Injectable
Global Myocardial Infarction Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Myocardial Infarction Market, By Region:
North America
By Drug Class:
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Antithrombotic Agents
Beta-adrenergic Blockers
Vasodilators
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin-receptor Blockers
Analgesics
Thrombolytics
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Antithrombotic Agents
Beta-adrenergic Blockers
Vasodilators
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin-receptor Blockers
Analgesics
Thrombolytics
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Antithrombotic Agents
Beta-adrenergic Blockers
Vasodilators
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin-receptor Blockers
Analgesics
Thrombolytics
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Antithrombotic Agents
Beta-adrenergic Blockers
Vasodilators
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin-receptor Blockers
Analgesics
Thrombolytics
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East
By Drug Class:
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Antithrombotic Agents
Beta-adrenergic Blockers
Vasodilators
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin-receptor Blockers
Analgesics
Thrombolytics
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Antithrombotic Agents
Beta-adrenergic Blockers
Vasodilators
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin-receptor Blockers
Analgesics
Thrombolytics
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Bristol-Myers Squibb Co *
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
Bayer AG
Johnson & Johnson Services Inc.
Sanofi S.A.
Novartis International AG
AstraZeneca plc.
Daiichi Sankyo Co Ltd
Boehringer Ingelheim International GmbH
Pfizer Inc.
Merck KGaA.

“*” marked represents similar segmentation in other categories in the respective section.